Innate Pharma moves on from a trial disaster with a €40M in-licensing pact with Novo Nordisk
Just four months after its lead therapy lirilumab flunked a mid-stage test fighting acute myeloid leukemia, France’s Innate Pharma has exchanged a chunk of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
